Literature DB >> 14711340

Prospects for vaccine development against Buruli disease.

Kris Huygen1.   

Abstract

Buruli disease, caused by Mycobacterium ulcerans, is an emerging infectious disease in tropical areas, particularly West Africa, which can cause deep necrotizing skin lesions, called Buruli ulcer. Buruli disease affects all age groups but about 50% of the cases are diagnosed in children. There is no evidence that Buruli disease is transmitted by direct person-to-person contact and it is very likely that contaminated water of rivers, swamps and lakes serves as the wildlife reservoir of M. ulcerans. This review briefly discusses the epidemiology, microbiology, pathology and treatment of the disease. It describes in detail the current knowledge of the immune response and focuses on the studies that have dealt with vaccination. Finally, experimental approaches for future immunoprophylaxis are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711340     DOI: 10.1586/14760584.2.4.561

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  8 in total

Review 1.  Pathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens.

Authors:  Laure Guenin-Macé; Reid Oldenburg; Fabrice Chrétien; Caroline Demangel
Journal:  Cell Mol Life Sci       Date:  2014-01-21       Impact factor: 9.261

2.  A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice.

Authors:  Audrey Tanghe; Pierre-Yves Adnet; Tatiana Gartner; Kris Huygen
Journal:  Infect Immun       Date:  2007-02-26       Impact factor: 3.441

Review 3.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

Review 4.  Buruli ulcer disease: prospects for a vaccine.

Authors:  Kris Huygen; Ohene Adjei; Dissou Affolabi; Gisela Bretzel; Caroline Demangel; Bernhard Fleischer; Roch Christian Johnson; Jorge Pedrosa; Delphin M Phanzu; Richard O Phillips; Gerd Pluschke; Vera Siegmund; Mahavir Singh; Tjip S van der Werf; Mark Wansbrough-Jones; Françoise Portaels
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402

5.  Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control.

Authors:  Paul D R Johnson; Timothy Stinear; Pamela L C Small; Gerd Pluschke; Richard W Merritt; Francoise Portaels; Kris Huygen; John A Hayman; Kingsley Asiedu
Journal:  PLoS Med       Date:  2005-04-26       Impact factor: 11.069

6.  IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with Mycobacterium ulcerans infection.

Authors:  Aloysius D Loglo; Richard O Phillips; Michael Frimpong; Mabel Sarpong Duah; Fred Sarfo; Francisca N Sarpong; Bernadette Agbavor; Justice K Boakye-Appiah; Kabiru M Abass; Mathias Dongyele; Margaret Frempong; Sacha Pidot; Mark Wansbrough-Jones; Timothy P Stinear; Virginie Roupie; Kris Huygen
Journal:  PeerJ       Date:  2018-07-31       Impact factor: 2.984

7.  Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting.

Authors:  Audrey Tanghe; Jean-Pierre Dangy; Gerd Pluschke; Kris Huygen
Journal:  PLoS Negl Trop Dis       Date:  2008-03-19

8.  Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease.

Authors:  Richard O Phillips; Fred S Sarfo; Jordi Landier; Reid Oldenburg; Michael Frimpong; Mark Wansbrough-Jones; Kabiru Abass; William Thompson; Mark Forson; Arnaud Fontanet; Fatoumata Niang; Caroline Demangel
Journal:  PLoS Negl Trop Dis       Date:  2014-04-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.